GEN3d
JPM: Roche Licenses Dyno Therapeutics’ AAV Vector for Neurological Gene Therapy
Roche has exercised its option to license a novel capsid from Dyno Therapeutics for use in a gene therapy program for an ...
Insmed’s gene therapy poised to challenge DMD landscape after IND clearance
Currently, the DMD treatment landscape includes Sarepta’s Elevidys (delandistrogene moxeparvovec), the first FDA-approved ...
New Atlas1d
Heart attack damage could be reversed by reactivating dormant gene
Heart attacks are dangerous not just because of the initial event, but the long-term damage afterwards. Now scientists have ...
Medscape3d
Gene Therapy in Hemophilia: High Hopes and Costs, Low Uptake
Life-changing gene therapies for hemophilia have become available, yet many patients and providers have not yet rushed to try ...
BioSpace5d
5 Cardio Gene Therapies on the Near Horizon
Benefiting from technological and conceptual groundwork and positive early data, gene therapies are advancing in the clinic ...
FierceBiotech5d
RegenXBio sells Hunter syndrome gene therapy's U.S., Asia commercial rights for $110M upfront
With an FDA approval submission for RegenXBio’s Hunter syndrome gene therapy already underway, the biopharma has now ...
The American Journal of Managed Care6d
Standardized Measurements Needed for AAVs in Gene Therapy, Study Finds
Common measurements for modified adeno-associated viruses (AAVs), a gene therapy delivery method, showed substantial ...
Gene editing extends lifespan in mouse model of prion disease
Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends ...
TMCnet2d
Boro Dropulic to Share Pivotal Insights at Advanced Therapies Week on January 21-22, 2025
Plenary Panel: "Innovating for the Future of Cell and Gene Therapies" Date: January 21, 2025 Time: 9:00 - 10:30 CST Highlights: Dr. Dropulic will join an esteemed panel to explore challenges and ...